Efficacy and safety of native and recombinant zona pellucida immunocontraceptive vaccines formulated with non-Freund’s adjuvants in donkeys
| dc.contributor.author | French, Hilari | |
| dc.contributor.author | Segabinazzi, Lorenzo | |
| dc.contributor.author | Middlebrooks, Brittany | |
| dc.contributor.author | Peterson, Erik | |
| dc.contributor.author | Schulman, M.L. (Martin) | |
| dc.contributor.author | Roth, Robyn | |
| dc.contributor.author | Crampton, Michael | |
| dc.contributor.author | Conan, Anne | |
| dc.contributor.author | Marchi, Silvia | |
| dc.contributor.author | Gilbert, Trevor | |
| dc.contributor.author | Knobel, Darryn Leslie | |
| dc.contributor.author | Bertschinger, Hendrik Jan | |
| dc.date.accessioned | 2023-03-09T09:43:08Z | |
| dc.date.available | 2023-03-09T09:43:08Z | |
| dc.date.issued | 2022-11-24 | |
| dc.description | SUPPLEMENTARY MATERIAL : FIGURE S1: Progesterone concentration of jennies vaccinated with recombinant zona pellucida vaccine (reZP, green lines), native porcine zona pellucida (pZP, red lines), or placebo (Control, black lines) from Day 70 to the day of pregnancy diagnosis. Jennies were vaccinated with three doses of reZP on Days 70, 35 and 0. For both pZP and Control, the primary dose and the booster were administered on Days 35 and 0. FIGURE S2: Effect of antibody titer at Day 35 (D35) on time to ovarian shutdown in the pZP and reZP groups combined. The solid line shows the shutdown rate relative to the mean D35 antibody titer as the reference. The dashed lines show the 95% confidence intervals. FIGURE S3: Effect of antibody titer at Day 35 (D35) on time to pregnancy in the pZP and reZP groups combined. The solid line shows the pregnancy rate relative to the mean D35 antibody titer as the reference. The dashed lines show the 95% confidence intervals. | en_US |
| dc.description.abstract | This study aimed to test zona pellucida (ZP) vaccines’ immunocontraceptive efficacy and safety when formulated with non-Freund’s adjuvant (6% Pet Gel A and 500 Mg Poly(I:C)). Twenty-four jennies were randomly assigned to three treatment groups: reZP (n = 7) received three doses of recombinant ZP vaccine; pZP (n = 9) received two doses of native porcine ZP; and Control group (n = 8) received two injections of placebo. Jennies were monitored weekly via transrectal ultrasonography and blood sampling for serum progesterone profiles and anti-pZP antibody titres. In addition, adverse effects were inspected after vaccination. Thirty-five days after the last treatment, jacks were introduced to each group and rotated every 28 days. Vaccination with both pZP and reZP was associated with ovarian shutdown in 44% (4/9) and 71% (4/7) of jennies, 118 33 and 91 20 days after vaccination, respectively (p > 0.05). Vaccination delayed the chances of a jenny becoming pregnant (p = 0.0005; Control, 78 31 days; pZP, 218 69 days; reZP, 244 104 days). Anti-pZP antibody titres were elevated in all vaccinated jennies compared to Control jennies (p < 0.05). In addition, only mild local injection site reactions were observed in the jennies after treatment. In conclusion, ZP vaccines formulated with non-Freund’s adjuvant effectively controlled reproduction in jennies with only minor localised side effects. | en_US |
| dc.description.department | Production Animal Studies | en_US |
| dc.description.department | Veterinary Tropical Diseases | en_US |
| dc.description.librarian | am2023 | en_US |
| dc.description.sponsorship | The Botstiber Foundation and internal grant from Ross University School of Veterinary Medicine. Development of recombinant ZP and testing in a series of mouse and horse trials was funded by a grant awarded by Technology Innovation Agency, Pretoria, South Africa to the University of Pretoria and the Council for Scientific and Industrial Research. | en_US |
| dc.description.uri | https://www.mdpi.com/journal/vaccines | en_US |
| dc.identifier.citation | French, H.; Segabinazzi, L.; Middlebrooks, B.; Peterson, E.; Schulman, M.; Roth, R.; Crampton, M.; Conan, A.; Marchi, S.; Gilbert, T.; et al. Efficacy and Safety of Native and Recombinant Zona Pellucida Immunocontraceptive Vaccines Formulated with Non-Freund’s Adjuvants in Donkeys. Vaccines 2022, 10, 1999. https://DOI.org/10.3390/vaccines10121999. | en_US |
| dc.identifier.issn | 2076-393X (online) | |
| dc.identifier.other | 10.3390/vaccines10121999 | |
| dc.identifier.uri | https://repository.up.ac.za/handle/2263/90050 | |
| dc.language.iso | en | en_US |
| dc.publisher | MDPI | en_US |
| dc.rights | © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. | en_US |
| dc.subject | Contraception | en_US |
| dc.subject | Infertility | en_US |
| dc.subject | Asinines | en_US |
| dc.subject | Ovarian suppression | en_US |
| dc.subject | Fertility | en_US |
| dc.subject | Zona pellucida | en_US |
| dc.subject | Non-Freund’s adjuvant | en_US |
| dc.title | Efficacy and safety of native and recombinant zona pellucida immunocontraceptive vaccines formulated with non-Freund’s adjuvants in donkeys | en_US |
| dc.type | Article | en_US |